TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23415635
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine 60 μg
Study: 23415635
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine 300 μg
Study: 19738091
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (4 mug/kg/min)
Study: 19738091
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no dopamine treatment)
Study: 7519132
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU bolus followed by 0.5 x 10(6) KIU/h continuous infusion)
Study: 21771973
Drug: Atorvastatin, 10
Normalized name: Amlodipine Besylate-Atorvastatin, 10 mg-80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 10 mg daily
Study: 18957811
Drug: Controlled-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release nifedipine (nifedipine CR) plus valsartan
Study: 6535843
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment in the program
Study: 3467975
Drug: Citalopram 40
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 40 mg
Study: 31625480
Drug: 2‐iminobiotin (2‐IB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐iminobiotin (2‐IB) 0.6 mg/kg, infused over periods between 15 min and 4 h, and repeated doses escalating from 0.6 mg/kg to 12 mg/kg every 4 h for 6 administrations.
Study: 31625480
Drug: Repeated iv
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated iv dosing of 2‐IB in an acute peripheral hypoxic ischemia model.
Study: 30125688
Drug: Daily medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily medication group (PrEP)
Study: 20533546
Drug: Canakinumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (all doses)
Study: 15877288
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/d) for 6 months
Study: 8859934
Drug: Mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibefradil 50 or 100 mg/day
Study: 6723209
Drug: Ethanol (BP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (BP; 0.5 g/kg body weight) at 21 degrees C
Study: 6723209
Drug: Ethanol (BP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (BP; 0.5 g/kg body weight) at 30 degrees C
Study: 6723209
Drug: Ethanol (BP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (BP; 1.0 g/kg body weight) at 21 degrees C
Study: 22588407
Drug: Periarticular injection
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periarticular injection (PAI)
Study: 21911616
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (0.75 L, 9.3 mmol nitrate; H-BR)
Study: 19234816
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus morphine
Study: 17009531
Drug: Integrated method
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated method (operation + Chinese medicine + dexamethasone + vitamin E)
Study: 17009531
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine + dexamethasone + vitamin E
Study: 14643269
Drug: Amiodarone (200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200mg orally 3 times a day) plus enalapril (10mg twice a day)
Study: 7933438
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition including a conventional amino acid solution (control group)
Study: 7933438
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition including the same amino acid solution supplemented with glycyl-glutamine (GLN group)
Study: 3119449
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg) in smokers
Study: 3119449
Drug: Misoprostol (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (800 mcg) in smokers
Study: 25706948
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pregabalin orally preoperatively
Study: 16433711
Drug: NPH-based multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH-based multiple daily insulin injections (MDI)
Study: 12945134
Drug: Millimetric electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Millimetric electromagnetic radiation (MER) combined therapy
Study: 12945134
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with 5.6 mm radiation
Study: 9357123
Drug: Biphasic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biphasic insulin administered twice a day
Study: 9357123
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lente insulin)
Study: 21181026
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose ROM Therapy (rifampin, ofloxacin, minocycline)
Study: 21181026
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose ROM Therapy
Study: 18211994
Drug: Ethanol (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (approximately 80 mg per 100 ml)
Study: 16940700
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention group consuming an average of 371.4 g/day of Okinawan vegetables for 14 days
Study: 11173715
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (8 week program of aerobic exercise at 75% VO(2) peak, 45 min, twice a week and intermittent exercise once a week)
Study: 9098873
Drug: Understanding of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Understanding of medication directions
Study: 1490224
Drug: Caffeine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (7 mg kg‐1)
Study: 21450995
Drug: AS03(A)‐adjuvanted double
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)‐adjuvanted double dose (3.75 μg hemagglutinin)
Study: 21450995
Drug: Nonadjuvanted single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted single dose
Study: 21450995
Drug: Nonadjuvanted double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonadjuvanted double dose
Study: 15191200
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential regimen (rabeprazole 20 mg b.i.d. + amoxycillin 1 g b.i.d. for 5 days, followed by rabeprazole 20 mg b.i.d. + clarithromycin 500 mg b.i.d. + tinidazole 500 mg b.i.d. for 5 days)
Study: 23862170
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy
Study: 17597398
Drug: 10-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day triple therapy
Study: 11041467
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase (UK) infusion at 30,000 U/h via each port concurrently, total 250,000 U
Study: 16569550
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic agent
Study: 9161237
Drug: Intradermal local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal local anesthetic
Study: 6421082
Drug: Both preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both preparations (vaginal cream and suppository)
Study: 30409792
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 once per week or 175 mg/m2 every 2 weeks)
Study: 11851637
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (Evra/Ortho Evra) applied on abdomen
Study: 11851637
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (Evra/Ortho Evra) applied on buttock
Study: 11851637
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (Evra/Ortho Evra) applied on torso
Study: 10335722
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg daily for 2 months
Study: 10335722
Drug: Etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 400 mg daily for 6 months
Study: 8951188
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg or 200 mg oral doses of nefazodone (NEF) as single doses on Day 1 and multiple (twice daily) doses on Days 12-22.
Study: 8951188
Drug: Multiple dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of nefazodone (NEF).
Study: 27025586
Drug: Endocrine Treatment
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Treatment (ET) alone
Study: 31786279
Drug: Endocrine Treatment
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Treatment (ET) + 70 Gy prostatic Radiation Therapy (RT)
Study: 31786279
Drug: Endocrine Treatment
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Treatment (ET) with salvage RT
Study: 26255208
Drug: Nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 100 mg, twice daily for 5 days
Study: 21398094
Drug: Adjunctive SAMe
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive SAMe
Study: 19404900
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 100 microg daily for 3 days
Study: 17224471
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (enalapril 10 mg PO), angiotensin II receptor blocker (losartan 100 mg PO, eprosartan 600 mg PO)
Study: 28438923
Drug: Reduced-clavulanate A/C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-clavulanate A/C formulation (90 mg amoxicillin/3.2 mg clavulanate/kg/day for 10 days)
Study: 28438923
Drug: Reduced-clavulanate A/C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-clavulanate A/C formulation (80 mg amoxicillin/2.85 mg clavulanate/kg/day for 10 days)
Study: 28438923
Drug: Standard A/C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard A/C regimen (90 mg amoxicillin/6.4 mg clavulanate/kg/day)
Study: 22025143
Drug: Capecitabine (intermittent:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (intermittent: 1,000 mg/m² twice daily for 14 of every 21 days; n = 107)
Study: 22025143
Drug: Capecitabine (continuous:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (continuous: 650 mg/m² twice daily for 21 of every 21 days; n = 107)
Study: 22025143
Drug: CMF (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (oral cyclophosphamide 100 mg/m² days 1 to 14, intravenous methotrexate 40 mg/m² and fluorouracil 600 mg/m² on days 1 and 8 every 28 days; n = 109)
Study: 15629834
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (4 mg)
Study: 11105539
Drug: Flutrimazole 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 2% cream (regimen B)
Study: 11105539
Drug: Flutrimazole 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutrimazole 4% cream (regimen C)
Study: 11105539
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (regimen D)
Study: 3890519
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 10% sulfacetamide sodium ophthalmic solution
Study: 20975053
Drug: 1.5 μg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg/min human αCGRP infusion
Study: 11144401
Drug: Cefdinir oral
Normalized name: cefdinir Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir oral suspension
Study: 16507381
Drug: Amoxicillin/clavulanate potassium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate potassium, cefprozil, azithromycin, or generic amoxicillin
Study: 3698460
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg lorazepam
Study: 3698460
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg lorazepam
Study: 29277822
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg every 2 weeks) and cyclophosphamide (150-250 mg/m2) added to a combination of gemcitabine, fluorouracil, leucovorin, irinotecan and a platinum analogue.
Study: 20083352
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection
Study: 16140397
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine followed by a 23-valent pneumococcal polysaccharide booster
Study: 12499347
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (ferrous sulfate 60 mg Fe once daily for 8 weeks)
Study: 27888542
Drug: Non-extended infusion
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-extended infusion (NEI) piperacillin/tazobactam (30-minute infusion)
Study: 27888542
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion (EI) piperacillin/tazobactam
Study: 26353825
Drug: VIPP-V (Video-feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIPP-V (Video-feedback Intervention to promote Positive Parenting) in combination with care-as-usual
Study: 23531117
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg drospirenone/0.5 mg 17β-estradiol (DRSP/E2)
Study: 21505096
Drug: C.E.R.A. 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. 1.2 μg/kg Q4W
Study: 19767815
Drug: 0% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% glucose solution
Study: 18840313
Drug: 2% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% glucose solution
Study: 24668608
Drug: 10% glucose
Normalized name: Dextrose 10% Oral Solution [SIMILAC 10% GLUCOSE WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glucose solution
Study: 19767815
Drug: Hypertonic carbohydrate-electrolyte
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic carbohydrate-electrolyte solutions
Study: 18204744
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized grass/rye mix extract
Study: 305734
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (30 mg) alone
Study: 31863561
Drug: Intramyocardial injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAEPICARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramyocardial injections of autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Study: 19318667
Drug: Glycopyrrolate (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (0.005 mg/kg; n = 336)
Study: 19318667
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg/kg; n = 339)
Study: 19318667
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 mL of normal saline solution; n = 325)
Study: 15014015
Drug: Temozolomide (TEM)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TEM) administered orally daily on days 1-5 and BCNU administered intravenously either on day 1 before TEM (Seq B‐‐>T) or day 5 after TEM (Seq T‐‐>B).
Study: 2755859
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine (MS Contin, Purdue Frederick Co.)
Study: 1752851
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route of administration
Study: 28492195
Drug: Inhalation route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation route of administration
Study: 23273434
Drug: Bortezomib 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.5 mg/m² biweekly on days 1, 4, 8, and 11 of a 21-day cycle (arm A)
Study: 16855170
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (14 patients on other anti-TNF therapies and 20 negative controls)
Study: 9029744
Drug: 12.5-cm2 once-a-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5-cm2 once-a-week adhesive patch
Study: 3263890
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of prednisone given daily for 5 days
Study: 28502831
Drug: Sucralose (333.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralose (333.3 mg, encapsulated, 3x/day at mealtimes)
Study: 16139331
Drug: Warfarin (INR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR 2.8‐4.2)
Study: 10776741
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg daily
Study: 8438096
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol controlled release (SCR) 8 mg b.d.
Study: 26242401
Drug: Interactive VRET
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive VRET plus conventional analgesics
Study: 26242401
Drug: Conventional analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesics alone
Study: 12743142
Drug: Whole-pelvic radiotherapy
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvic radiotherapy (WP RT) + Adjuvant hormonal therapy (AHT)
Study: 12743142
Drug: Prostate-only radiotherapy
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-only radiotherapy (PO RT) + Adjuvant hormonal therapy (AHT)
Study: 12743142
Drug: Adjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormonal therapy (AHT)
Study: 29788433
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (400 g daily for 2 weeks)
Study: 10628889
Drug: Imipramine (50-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50-100 mg/day)
Study: 8688982
Drug: Moscontin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moscontin (30 mg)
Study: 2091623
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (400 to 1600 mg)
Study: 7350799
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline (0.5 mg)
Study: 15830222
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 20 mg
Study: 21514093
Drug: Hydrocortisone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone at 1.5 μg/kg per minute (STRESS)
Study: 21514093
Drug: Hydrocortisone at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone at 3.0 μg/kg per minute (PHARM)
Study: 11356728
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic
Study: 3595575
Drug: Gastrozepin 10
Normalized name: Gastrotsepin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrozepin 10 mg
Study: 19630495
Drug: Narcotics and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotics and acetaminophen alone
Study: 18555931
Drug: Novopharm tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novopharm tablet
Study: 10442525
Drug: Epinastine 20
Normalized name: epinastine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine 20 mg
Study: 8621275
Drug: RRP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRP plus neoadjuvant hormonal therapy
Study: 8621275
Drug: RRP without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RRP without hormonal therapy
Study: 19592234
Drug: Adjuvant therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapies
Study: 30548555
Drug: ProDesign R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProDesign R [PDR; size 25, .06 taper; Easy, Belo Horizonte, Brazil]
Study: 30548555
Drug: Mtwo [MO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtwo [MO; size 25, .06 taper; VDW, Munich, Germany]
Study: 30548555
Drug: Reciproc [REC;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reciproc [REC; size 25, .08 taper; VDW, Munich, Germany]
Study: 30278067
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (10 mg/kg)
Study: 30278067
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3 g)
Study: 30278067
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo (60 ml physiological saline)
Study: 2193199
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no insulin treatment)